AMPLITUDE — efpeglenatide
The cardiovascular and renal outcome programme for the exendin-based long-acting agonist efpeglenatide. The Institute holds no separate monograph for efpeglenatide and records the programme against the exenatide monograph, which covers the exendin-derived structural class.
The cardiovascular and renal outcome programme for the exendin-based long-acting agonist efpeglenatide. The Institute holds no separate monograph for efpeglenatide and records the programme against the exenatide monograph, which covers the exendin-derived structural class.
Sponsor class: Manufacturer-sponsored. First record: 2018.
Records in this programme
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| AMPLITUDE-O | Exenatide | Phase 3 | Reported | Event-driven cardiovascular outcome trial | 4,076 | 2021 | Moderate |
| AMPLITUDE-O-BODY-COMPprogramme record | Exenatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2021 | Very low |
| AMPLITUDE-O-QOLprogramme record | Exenatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2021 | Very low |
| AMPLITUDE-O-REGIONAL-CNprogramme record | Exenatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2021 | Very low |
| AMPLITUDE-O-REGIONAL-JPprogramme record | Exenatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2021 | Very low |